Cargando…

Impact of JAK2 V617F Mutation on Hemogram Variation in Patients with Non-Reactive Elevated Platelet Counts

BACKGROUND: Non-reactive platelet counts elevation occurs mainly in myeloproliferative disorders (MPDs), which have been reported to be closely associated with JAK2 V617F mutation. Complete blood cell count (CBC) is essential in diagnosis of MPDs, however, the impact of JAK2 V617F mutation on the pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Juan, Ye, Yuanxin, Zeng, Shugen, Zhou, Yi, Mao, Zhigang, Song, Xingbo, Ying, Binwu, Lu, Xiaojun, Jiang, Hong, Wang, Lanlan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3585181/
https://www.ncbi.nlm.nih.gov/pubmed/23469088
http://dx.doi.org/10.1371/journal.pone.0057856
_version_ 1782261114364493824
author Zhou, Juan
Ye, Yuanxin
Zeng, Shugen
Zhou, Yi
Mao, Zhigang
Song, Xingbo
Ying, Binwu
Lu, Xiaojun
Jiang, Hong
Wang, Lanlan
author_facet Zhou, Juan
Ye, Yuanxin
Zeng, Shugen
Zhou, Yi
Mao, Zhigang
Song, Xingbo
Ying, Binwu
Lu, Xiaojun
Jiang, Hong
Wang, Lanlan
author_sort Zhou, Juan
collection PubMed
description BACKGROUND: Non-reactive platelet counts elevation occurs mainly in myeloproliferative disorders (MPDs), which have been reported to be closely associated with JAK2 V617F mutation. Complete blood cell count (CBC) is essential in diagnosis of MPDs, however, the impact of JAK2 V617F mutation on the patients’ hemogram variation remains not clear. METHODS: JAK2 V617F mutation was detected by allele specific real-time quantitative fluorescence PCR (AS-qPCR). RESULTS: Of the 402 non-reactive platelet elevating patients, JAK2 V617F mutation was detected in 222 (55.2%) patients. RBC counts, WBC counts, platelet-large contrast ratio (P-LCR), platelet distribution width (PDW) and mean platelet volume (MPV) were much higher in JAK2 V617F mutated patients, except platelet counts. In addition, when the patients were classified into subgroups by blood cell counts, it was found that JAK2 V617F mutation rate increased progressively with the increase of RBC counts and WBC counts, other than platelet counts. Furthermore, trilineage hyperplasia group showed highest JAK2 V617F mutation rate (93.26%), followed by the bilineage hyperplasia groups. Lastly, JAK2 V617F mutant allele burden was found much higher in polycythemia vera (PV) patients [median(P(25)–P(75)): 45.02%(35.12%–54.22%)] than in essential thrombocythemia (ET) patients [median(P(25)–P(75)): 28.23%(17.77%–41.66%)], and that it increased with WBC counts (r = 0.393, p = 0.000) and RBC counts(r = 0.215, p = 0.001), other than platelet counts (r = −0.051, p = 0.452). Further analysis revealed that in ET patients, JAK2 V617F mutant allele burden correlated with WBC counts and platelet counts positively, other than RBC counts, while in PV patients, it correlated with WBC counts and RBC counts positively, but not platelet counts. CONCLUSIONS: JAK2 V617F mutation occurs frequently in patients with non-reactive elevated platelet counts. The presence of JAK2 V617F mutation has great impact on hemogram variation, including RBC counts, WBC counts, platelet parameters and lineage hyperplasia, but not on platelet counts. Besides, JAK2 V617F mutant allele burden affects the blood cell proliferation pattern.
format Online
Article
Text
id pubmed-3585181
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-35851812013-03-06 Impact of JAK2 V617F Mutation on Hemogram Variation in Patients with Non-Reactive Elevated Platelet Counts Zhou, Juan Ye, Yuanxin Zeng, Shugen Zhou, Yi Mao, Zhigang Song, Xingbo Ying, Binwu Lu, Xiaojun Jiang, Hong Wang, Lanlan PLoS One Research Article BACKGROUND: Non-reactive platelet counts elevation occurs mainly in myeloproliferative disorders (MPDs), which have been reported to be closely associated with JAK2 V617F mutation. Complete blood cell count (CBC) is essential in diagnosis of MPDs, however, the impact of JAK2 V617F mutation on the patients’ hemogram variation remains not clear. METHODS: JAK2 V617F mutation was detected by allele specific real-time quantitative fluorescence PCR (AS-qPCR). RESULTS: Of the 402 non-reactive platelet elevating patients, JAK2 V617F mutation was detected in 222 (55.2%) patients. RBC counts, WBC counts, platelet-large contrast ratio (P-LCR), platelet distribution width (PDW) and mean platelet volume (MPV) were much higher in JAK2 V617F mutated patients, except platelet counts. In addition, when the patients were classified into subgroups by blood cell counts, it was found that JAK2 V617F mutation rate increased progressively with the increase of RBC counts and WBC counts, other than platelet counts. Furthermore, trilineage hyperplasia group showed highest JAK2 V617F mutation rate (93.26%), followed by the bilineage hyperplasia groups. Lastly, JAK2 V617F mutant allele burden was found much higher in polycythemia vera (PV) patients [median(P(25)–P(75)): 45.02%(35.12%–54.22%)] than in essential thrombocythemia (ET) patients [median(P(25)–P(75)): 28.23%(17.77%–41.66%)], and that it increased with WBC counts (r = 0.393, p = 0.000) and RBC counts(r = 0.215, p = 0.001), other than platelet counts (r = −0.051, p = 0.452). Further analysis revealed that in ET patients, JAK2 V617F mutant allele burden correlated with WBC counts and platelet counts positively, other than RBC counts, while in PV patients, it correlated with WBC counts and RBC counts positively, but not platelet counts. CONCLUSIONS: JAK2 V617F mutation occurs frequently in patients with non-reactive elevated platelet counts. The presence of JAK2 V617F mutation has great impact on hemogram variation, including RBC counts, WBC counts, platelet parameters and lineage hyperplasia, but not on platelet counts. Besides, JAK2 V617F mutant allele burden affects the blood cell proliferation pattern. Public Library of Science 2013-02-28 /pmc/articles/PMC3585181/ /pubmed/23469088 http://dx.doi.org/10.1371/journal.pone.0057856 Text en © 2013 Zhou et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Zhou, Juan
Ye, Yuanxin
Zeng, Shugen
Zhou, Yi
Mao, Zhigang
Song, Xingbo
Ying, Binwu
Lu, Xiaojun
Jiang, Hong
Wang, Lanlan
Impact of JAK2 V617F Mutation on Hemogram Variation in Patients with Non-Reactive Elevated Platelet Counts
title Impact of JAK2 V617F Mutation on Hemogram Variation in Patients with Non-Reactive Elevated Platelet Counts
title_full Impact of JAK2 V617F Mutation on Hemogram Variation in Patients with Non-Reactive Elevated Platelet Counts
title_fullStr Impact of JAK2 V617F Mutation on Hemogram Variation in Patients with Non-Reactive Elevated Platelet Counts
title_full_unstemmed Impact of JAK2 V617F Mutation on Hemogram Variation in Patients with Non-Reactive Elevated Platelet Counts
title_short Impact of JAK2 V617F Mutation on Hemogram Variation in Patients with Non-Reactive Elevated Platelet Counts
title_sort impact of jak2 v617f mutation on hemogram variation in patients with non-reactive elevated platelet counts
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3585181/
https://www.ncbi.nlm.nih.gov/pubmed/23469088
http://dx.doi.org/10.1371/journal.pone.0057856
work_keys_str_mv AT zhoujuan impactofjak2v617fmutationonhemogramvariationinpatientswithnonreactiveelevatedplateletcounts
AT yeyuanxin impactofjak2v617fmutationonhemogramvariationinpatientswithnonreactiveelevatedplateletcounts
AT zengshugen impactofjak2v617fmutationonhemogramvariationinpatientswithnonreactiveelevatedplateletcounts
AT zhouyi impactofjak2v617fmutationonhemogramvariationinpatientswithnonreactiveelevatedplateletcounts
AT maozhigang impactofjak2v617fmutationonhemogramvariationinpatientswithnonreactiveelevatedplateletcounts
AT songxingbo impactofjak2v617fmutationonhemogramvariationinpatientswithnonreactiveelevatedplateletcounts
AT yingbinwu impactofjak2v617fmutationonhemogramvariationinpatientswithnonreactiveelevatedplateletcounts
AT luxiaojun impactofjak2v617fmutationonhemogramvariationinpatientswithnonreactiveelevatedplateletcounts
AT jianghong impactofjak2v617fmutationonhemogramvariationinpatientswithnonreactiveelevatedplateletcounts
AT wanglanlan impactofjak2v617fmutationonhemogramvariationinpatientswithnonreactiveelevatedplateletcounts